-
1
-
-
84913555304
-
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
-
Plavina T, Subramanyam M, Bloomgren G, et al., Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 802-812.
-
(2014)
Ann Neurol
, vol.76
, pp. 802-812
-
-
Plavina, T.1
Subramanyam, M.2
Bloomgren, G.3
-
2
-
-
84861022041
-
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
-
Bloomgren G, Richman S, Hotermans C, et al., Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
-
(2012)
N Engl J Med
, vol.366
, pp. 1870-1880
-
-
Bloomgren, G.1
Richman, S.2
Hotermans, C.3
-
3
-
-
84904748984
-
Natalizumab: Risk stratification of individual patients with multiple sclerosis
-
Tur C, Montalban X,. Natalizumab: risk stratification of individual patients with multiple sclerosis. CNS Drugs 2014; 28: 641-648.
-
(2014)
CNS Drugs
, vol.28
, pp. 641-648
-
-
Tur, C.1
Montalban, X.2
-
4
-
-
77956387401
-
Anti-JC virus antibodies: Implications for PML risk stratification
-
Gorelik L, Lerner M, Bixler S, et al., Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
-
(2010)
Ann Neurol
, vol.68
, pp. 295-303
-
-
Gorelik, L.1
Lerner, M.2
Bixler, S.3
-
5
-
-
79960344014
-
Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring
-
Kappos L, Bates D, Edan G, et al., Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-758.
-
(2011)
Lancet Neurol
, vol.10
, pp. 745-758
-
-
Kappos, L.1
Bates, D.2
Edan, G.3
-
6
-
-
79958137883
-
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
-
O'Connor PW, Goodman A, Kappos L, et al., Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865.
-
(2011)
Neurology
, vol.76
, pp. 1858-1865
-
-
O'Connor, P.W.1
Goodman, A.2
Kappos, L.3
-
7
-
-
77956388036
-
Natalizumab dosage suspension: Are we helping or hurting?
-
West TW, Cree BA,. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395-399.
-
(2010)
Ann Neurol
, vol.68
, pp. 395-399
-
-
West, T.W.1
Cree, B.A.2
-
8
-
-
84902548597
-
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients
-
Sangalli F, Moiola L, Ferre L, et al., Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Mult Scler Relat Disord 2014; 3: 520-526.
-
(2014)
Mult Scler Relat Disord
, vol.3
, pp. 520-526
-
-
Sangalli, F.1
Moiola, L.2
Ferre, L.3
-
9
-
-
79951543155
-
Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy
-
Miravalle A, Jensen R, Kinkel RP,. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186-191.
-
(2011)
Arch Neurol
, vol.68
, pp. 186-191
-
-
Miravalle, A.1
Jensen, R.2
Kinkel, R.P.3
-
10
-
-
84905968845
-
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: Evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)
-
Clerico M, Schiavetti I, De Mercanti SF, et al., Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol 2014; 71: 954-960.
-
(2014)
JAMA Neurol
, vol.71
, pp. 954-960
-
-
Clerico, M.1
Schiavetti, I.2
De Mercanti, S.F.3
-
11
-
-
84893060675
-
We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?
-
Fragoso YD, Arruda NM, Arruda WO, et al., We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it? Expert Rev Neurother 2014; 14: 127-130.
-
(2014)
Expert Rev Neurother
, vol.14
, pp. 127-130
-
-
Fragoso, Y.D.1
Arruda, N.M.2
Arruda, W.O.3
-
12
-
-
84947790954
-
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
-
Iaffaldano P, Lucisano G, Pozzilli C, et al., Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain 2015; 138 (pt 11): 3275-3286.
-
(2015)
Brain
, vol.138
, pp. 3275-3286
-
-
Iaffaldano, P.1
Lucisano, G.2
Pozzilli, C.3
-
13
-
-
84899004764
-
Switching from natalizumab to fingolimod in multiple sclerosis: A French prospective study
-
Cohen M, Maillart E, Tourbah A, et al., Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014; 71: 436-441.
-
(2014)
JAMA Neurol
, vol.71
, pp. 436-441
-
-
Cohen, M.1
Maillart, E.2
Tourbah, A.3
-
14
-
-
84936999643
-
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
-
Kappos L, Radue EW, Comi G, et al., Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology 2015; 85: 29-39.
-
(2015)
Neurology
, vol.85
, pp. 29-39
-
-
Kappos, L.1
Radue, E.W.2
Comi, G.3
-
15
-
-
39049142995
-
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
-
Hauser SL, Waubant E, Arnold DL, et al., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
-
(2008)
N Engl J Med
, vol.358
, pp. 676-688
-
-
Hauser, S.L.1
Waubant, E.2
Arnold, D.L.3
-
17
-
-
84897025098
-
A changing treatment landscape for multiple sclerosis: Challenges and opportunities
-
Piehl F,. A changing treatment landscape for multiple sclerosis: challenges and opportunities. J Intern Med 2014; 275: 364-381.
-
(2014)
J Intern Med
, vol.275
, pp. 364-381
-
-
Piehl, F.1
-
18
-
-
84929468055
-
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
-
Dong-Si T, Richman S, Wattjes MP, et al., Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014; 1: 755-764.
-
(2014)
Ann Clin Transl Neurol
, vol.1
, pp. 755-764
-
-
Dong-Si, T.1
Richman, S.2
Wattjes, M.P.3
-
19
-
-
41849116363
-
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase i trial
-
Bar-Or A, Calabresi PA, Arnold D, et al., Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395-400.
-
(2008)
Ann Neurol
, vol.63
, pp. 395-400
-
-
Bar-Or, A.1
Calabresi, P.A.2
Arnold, D.3
-
20
-
-
77953335494
-
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
-
Naismith RT, Piccio L, Lyons JA, et al., Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010; 74: 1860-1867.
-
(2010)
Neurology
, vol.74
, pp. 1860-1867
-
-
Naismith, R.T.1
Piccio, L.2
Lyons, J.A.3
-
21
-
-
84857856422
-
Maximally tolerated versus minimally effective dose: The case of rituximab in multiple sclerosis
-
Nielsen AS, Miravalle A, Langer-Gould A, et al., Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Mult Scler 2012; 18: 377-378.
-
(2012)
Mult Scler
, vol.18
, pp. 377-378
-
-
Nielsen, A.S.1
Miravalle, A.2
Langer-Gould, A.3
-
22
-
-
70449418132
-
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
-
Hawker K, O'Connor P, Freedman MS, et al., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
-
(2009)
Ann Neurol
, vol.66
, pp. 460-471
-
-
Hawker, K.1
O'Connor, P.2
Freedman, M.S.3
-
23
-
-
76149093586
-
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
-
Kappos L, Radue EW, O'Connor P, et al., A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
-
(2010)
N Engl J Med
, vol.362
, pp. 387-401
-
-
Kappos, L.1
Radue, E.W.2
O'Connor, P.3
-
24
-
-
84901197534
-
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial
-
Calabresi PA, Radue EW, Goodin D, et al., Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-556.
-
(2014)
Lancet Neurol
, vol.13
, pp. 545-556
-
-
Calabresi, P.A.1
Radue, E.W.2
Goodin, D.3
-
25
-
-
76149140914
-
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
-
Cohen JA, Barkhof F, Comi G, et al., Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
-
(2010)
N Engl J Med
, vol.362
, pp. 402-415
-
-
Cohen, J.A.1
Barkhof, F.2
Comi, G.3
|